William A. Wegener

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat et al. · New England Journal of Medicine · 2019 · 850 citations

Medicine, Oncology, Pharmacology +17

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond et al. · Journal of Clinical Oncology · 2017 · 409 citations

Medicine, Oncology, Pharmacology +12

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio et al. · Annals of Oncology · 2021 · 375 citations

Medicine, Oncology, Pharmacology +17

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Alexander Starodub, Allyson J. Ocean, Manish A. Shah et al. · Clinical Cancer Research · 2015 · 344 citations · Full text

Medicine, Oncology, Pharmacology +17

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

Thomas Dörner, Joerg Kaufmann, William A. Wegener et al. · Arthritis Research & Therapy · 2006 · 307 citations · Full text

Life Sciences, Immunology, Pharmacology +16